Adaptimmune Therapeutics plc (ADAP)
NASDAQ: ADAP · Real-Time Price · USD
0.3000
0.00 (0.00%)
May 8, 2025, 4:00 PM EDT - Market closed
Adaptimmune Therapeutics Stock Forecast
ADAP's stock price has decreased by -72.73% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Adaptimmune Therapeutics stock have an average target of 1.83, with a low estimate of 1.40 and a high estimate of 3.00. The average target predicts an increase of 510.00% from the current stock price of 0.30.
Analyst Consensus: Strong Buy
* Price targets were last updated on Apr 1, 2025.
Analyst Ratings
The average analyst rating for Adaptimmune Therapeutics stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $3.5 → $3 | Strong Buy | Maintains | $3.5 → $3 | +900.00% | Apr 1, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $3 → $1.75 | Strong Buy | Maintains | $3 → $1.75 | +483.33% | Mar 26, 2025 |
| Wells Fargo | Wells Fargo | Hold Maintains $2 → $1.5 | Hold | Maintains | $2 → $1.5 | +400.00% | Mar 21, 2025 |
| Scotiabank | Scotiabank | Buy Maintains $3.15 → $1.4 | Buy | Maintains | $3.15 → $1.4 | +366.67% | Mar 21, 2025 |
| Mizuho | Mizuho | Buy Maintains $3 → $1.5 | Buy | Maintains | $3 → $1.5 | +400.00% | Nov 27, 2024 |
Financial Forecast
Revenue This Year
39.71M
from 178.03M
Decreased by -77.70%
Revenue Next Year
67.43M
from 39.71M
Increased by 69.81%
EPS This Year
-0.29
from -0.30
EPS Next Year
-0.19
from -0.29
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 63.8M | 89.8M | 157.7M | ||
| Avg | 39.7M | 67.4M | 130.4M | ||
| Low | 17.2M | 43.2M | 103.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -64.1% | 126.1% | 133.9% | ||
| Avg | -77.7% | 69.8% | 93.4% | ||
| Low | -90.4% | 8.8% | 54.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.07 | -0.02 | -0.01 |
| Avg | -0.29 | -0.19 | -0.15 |
| Low | -0.54 | -0.48 | -0.33 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.